J. Ledermann

发表

Predicting biomarkers for ovarian cancer using gene-expression microarrays

S. Henderson, C. Boshoff, T. Adib, 2004, British Journal of Cancer.

Antigens of lung cancer: results of the second international workshop on lung cancer antigens.

R. Souhami, L. Bobrow, P. Beverley, 1991, Journal of the National Cancer Institute.

Asymptomatic patient with an increasing concentration of CEA.

J. Ledermann, T. Arulampalam, D. C. Costa, 2001, The Lancet. Oncology.

Optimal treatment of early-stage ovarian cancer

J. Ledermann, A. Lissoni, N. Colombo, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Optimal fi rst-line treatment in ovarian cancer

J. Ledermann, F. Raja, N. Chopra, 2012 .

Optimal first-line treatment in ovarian cancer.

J. Ledermann, F. Raja, N. Chopra, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A call for prospective studies in early‐stage ovarian cancer

J. Ledermann, R. Naik, P. Cross, 2010, BJOG : an international journal of obstetrics and gynaecology.

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.

I. Vergote, U. Matulonis, S. Lau, 2020, Gynecologic oncology.

ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer

M. Buyse, E. Dreher, Torri, 1998, The Lancet.

Acutepulmonary embolism following airtravel

J. Ledermann, 1983 .

Acute pulmonary embolism following air travel

A. Keshavarzian, J. Ledermann, A. Keshavarzian, 1983, Postgraduate medical journal.

Malignant melanoma REPORT OF A MEETING OF PHYSICIANS AND SCIENTISTS, UNIVERSITY COLLEGE LONDON MEDICAL SCHOOL

J. Ledermann, H. Stauss, D. Dubois, 1992, The Lancet.

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial

D. Kerr, C. McArdle, R. Stephens, 2003, The Lancet.

Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer

R. James, D. Hochhauser, M. Seymour, 2002, British Journal of Cancer.

Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial

C. McArdle, J. Ledermann, R. James, 2002, The Lancet.

Primary tumour resection and survival in the palliative management of metastatic colorectal cancer.

J. Bridgewater, D. Hochhauser, N. Blunt, 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Is ectopic production of human chorionic gonadotrophin (hCG) or alpha fetoprotein (AFP) by tumours a marker of chemosensitivity?

S. M. Crawford, E. Newlands, G. Rustin, 1986, European journal of cancer & clinical oncology.

A phase II study of regional 2-weekly 5-fluorouracil infusion with intravenous folinic acid in the treatment of colorectal liver metastases.

D. Kerr, C. McArdle, I. Taylor, 1997, British Journal of Cancer.

Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study.

M. Gore, H. Gabra, I. Vergote, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference

N. Yanaihara, A. Okamoto, J. Ledermann, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting.

H. Comber, J. Rashbass, I. Vergote, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

AUC 2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol , a sensitizer of platinum cytotoxicity : the phase III OVATUREmulticenter randomized study

M. Gore, H. Gabra, I. Vergote, 2013 .

Chemotherapy for ovarian cancer--a consensus statement on standard practice.

H. Earl, M. Gore, G. Jayson, 1998, British Journal of Cancer.

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.

D. Provencher, M. Birrer, I. Vergote, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review.

M. Parmar, S. Burdett, J. Ledermann, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

V. Torri, G. Jayson, I. Floriani, 2003, Lancet.

Safety and dose modification for patients receiving niraparib

J. Ledermann, J. Berek, I. Vergote, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer

G. Jayson, D. Cruickshank, P. Wilkinson, 2005, British Journal of Cancer.

EMOP/CA chemotherapy for the treatment of aggressive non-Hodgkin's lymphomas.

E. Newlands, E. Boesen, G. Rustin, 1989, European journal of cancer & clinical oncology.

A phase‐i study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin a to suppress the immune response

K. Bagshawe, J. Ledermann, R. Begent, 1991, International journal of cancer.

A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice

D. Berney, J. Shamash, Susana Banerjee, 2019, European journal of cancer.

Cyclosporin A prevents the anti-murine antibody response to a monoclonal anti-tumour antibody in rabbits.

K. Bagshawe, J. Ledermann, R. Begent, 1988, British Journal of Cancer.

Use of second antibody in radioimmunotherapy.

K. Bagshawe, R. Pedley, P. Keep, 1987, NCI monographs : a publication of the National Cancer Institute.

Serum neurone-specific enolase and other neuroendocrine markers in lung cancer.

J. Ledermann, 1994, European journal of cancer.

Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).

D. Matei, J. Carmichael, C. Watkins, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of the central data analysis.

R. Souhami, L. Bobrow, P. Beverley, 1991, The British journal of cancer. Supplement.

Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.

M. Seymour, J. Ledermann, P. Leonard, 2001, The New England journal of medicine.

Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK.

H. Kitchener, J. Ledermann, G. Hall, 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial

G. Jayson, H. Hirte, S. Kaye, 2013 .

A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC).

G. Jayson, G. Rustin, H. Gabra, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.

P. Quirke, A. Maraveyas, R. Glynne-Jones, 2014 .

High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT).

P. Viens, F. Chauvin, J. Lotz, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Detection of the neural cell adhesion molecule (NCAM) in serum of patients with small‐cell lung cancer (SCLC) with “limited” or “extensive” disease, and bone‐marrow infiltration

G. Pelosi, F. Pasini, J. Ledermann, 1994, International journal of cancer. Supplement = Journal international du cancer. Supplement.

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.

I. Vergote, I. McNeish, S. Pignata, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer.

A. Oza, M. Carey, P. Beale, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

2759 Management of nausea and vomiting during treatment with the capsule (CAP) and tablet (TAB) formulations of the PARP inhibitor olaparib

M. Friedlander, U. Matulonis, S. Kaye, 2015 .

Cancer Research Campaign operation manual for control recommendations for products derived from recombinant DNA technology prepared for investigational administration to patients with cancer in phase I trials.

R. Begent, J. Mcvie, H. Zwierzina, 1993, European journal of cancer.

Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.

G. Rustin, W. Oster, J. Ledermann, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study.

J. Ledermann, G. Rustin, M. Friedlander, 2006, Gynecologic oncology.

Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).

M. Stockler, T. Fehm, A. Oza, 2019, Gynecologic oncology.

PROSPECTS FOR ANTIBODY-TARGETED RADIOTHERAPY OF CANCER

T. Wheldon, M. Slevin, J. Shepherd, 1986, The Lancet.

Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil.

D. Kerr, C. McArdle, J. Ledermann, 1995, Journal of Clinical Oncology.

3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations

A. Oza, J. Ledermann, E. Swisher, 2020 .

Biodistribution of a radiolabelled monoclonal antibody NY3D11 recognizing the neural cell adhesion molecule in tumour xenografts and patients with small-cell lung cancer.

S. Ward, G. Boxer, R. Pedley, 1998, British Journal of Cancer.

ESGO consensus conference recommendations on ovarian cancer : pathology and molecular biology , early and advanced stages , borderline tumours and recurrent disease

J. Ledermann, I. Vergote, I. McNeish, 2019 .

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.

D. Timmerman, J. Ledermann, R. Glasspool, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Dapsone in Allergic Vasculitis: Its Use in Henoch-Schönlein Disease following Vaccination 1

J. Ledermann, B. Hoffbrand, 1983, Journal of the Royal Society of Medicine.

The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumours.

G. Rustin, K. Bagshawe, J. Ledermann, 1994, British journal of urology.

Curable metastatic cancer in young women.

S. M. Crawford, J. Ledermann, K. Bagshawe, 1987, British medical journal.

IS PRODUCTION OF HUMAN CHORIONIC-GONADOTROPIN (HCG) OR ALPHA FETOPROTEIN (AFP) BY SOMATIC TUMORS A MARKER OF CHEMOSENSITIVITY

S. M. Crawford, G. Rustin, K. Bagshawe, 1986 .

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

R. Plummer, G. Rustin, M. Friedlander, 2016, Targeted Oncology.

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

C. Sessa, N. Colombo, C. Fotopoulou, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

The Systemic Treatment of Recurrent Ovarian Cancer revisited.

J. Ledermann, N. Colombo, F. Joly, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcome of epithelial ovarian cancer in women under 40 years of age treated with platinum-based chemotherapy.

J. Ledermann, G. Rustin, J. Ledermann, 1999, European journal of cancer.

Extrapulmonary small cell carcinoma.

J. Ledermann, 1992, Postgraduate medical journal.

Latest clinical evidence and further development of PARP inhibitors in ovarian cancer

S. Pignata, M. Mirza, J. Ledermann, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.

D. Alberts, M. Parmar, V. Torri, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.

J. Ledermann, G. Jayson, G. Rustin, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Weekly etoposide, methotrexate and actinomycin D, alternating with cyclophosphamide plus vincristine (EMA/CO): a phase II study in advanced gastric carcinoma.

E. Newlands, G. Rustin, K. Bagshawe, 1991, Clinical oncology (Royal College of Radiologists (Great Britain)).

A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.

M. Gore, G. Jayson, G. Rustin, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Update on first-line treatment of advanced ovarian carcinoma

J. Ledermann, J. Ledermann, Z. Kemp, 2013, International journal of women's health.

Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A.

R. Dale, K. Bagshawe, F. Searle, 1988, British Journal of Cancer.

Guidelines for resection of colorectal cancer liver metastases

R. Parks, J. Ledermann, O. Garden, 2006, Gut.

PHASE I/II STUDY OF CHIMERIC B72.3 ANTIBODY IN RADIOIMMUNOTHERAPY OF COLORECTAL-CARCINOMA

K. Bagshawe, J. Ledermann, D. Secher, 1990 .

Reliability of core needle biopsy for determining ER and HER 2 status in breast cancer

V. Gebski, R. Simes, G. Kristensen, 2013 .

Detection of small‐cell‐lung‐cancer cells in bone‐marrow aspirates by monoclonal antibodies NCC‐LU‐243, NCC‐LU‐246 and MLuCl

J. Ledermann, G. Pelosi, G. Cetto, 1994, International journal of cancer. Supplement = Journal international du cancer. Supplement.

carcinoembryonic antigen: phase I/Il study with comparative biodistribution of intact and F(ab') antibodies

L. Hope-Stone, J. L. Casey, P. Keep, 2007 .

Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer.

R. Dale, K. Bagshawe, P. Keep, 1989, British Journal of Cancer.

Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer.

A. Oza, M. Carey, P. Beale, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

J. Ledermann, P. Quirke, A. Maraveyas, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and dose modification for patients receiving niraparib.

J. Berek, I. Vergote, S. Ellard, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

C. Sessa, N. Colombo, C. Fotopoulou, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

965PEvaluation of tumour responses and olaparib efficacy in platinum-sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21)

A. Oza, C. Scott, I. Vergote, 2017 .

Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.

N. Yanaihara, A. Okamoto, M. Quinn, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Corrections to "Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".

C. Sessa, N. Colombo, C. Fotopoulou, 2018 .

Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer.

G. Rustin, J. Ledermann, P. W. Nicholson, 1996, European journal of gynaecological oncology.

Outcome of patients with unfavorable optimally cytoreduced ovarian cancer treated with chemotherapy and whole abdominal radiation.

A. Fyles, G. Thomas, J. Ledermann, 1991, Gynecologic oncology.

Clinical management of ovarian cancer

I. Vergote, S. Kaye, W. Hoskins, 2001 .

Br. J. Cancer

J. Ledermann, J. Ledermann, R. Begent, 1991 .

Iodine-131-MIBG therapy of a patient with carcinoid liver metastases.

P. Ell, R. Stein, J. Bomanji, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

G. Rustin, C. Sessa, S. Kaye, 2016, Targeted Oncology.

Correction to Lancet Oncol 2014; 15: 856. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

C. Gourley, P. Harter, J. Ledermann, 2015, The Lancet. Oncology.